Cumulative rate of relapse of lupus nephritis after successful treatment with cyclophosphamide

Arthritis and Rheumatism
E CirueloJ J Gomez-Reino

Abstract

To determine the cumulative rate of relapse of lupus nephritis that has been treated successfully with cyclophosphamide (CYC), and to estimate the association between time to relapse and demographic, clinical, laboratory, and treatment variables. This was an observational study of 48 systemic lupus erythematosus (SLE) patients who were treated successfully with CYC between 1979 and 1993 and followed up thereafter at 3 university hospitals. Demographic and clinical variables, laboratory data during the first month of nephritis, and therapy-related variables were recorded from charts. Renal biopsy specimens were retrieved and analyzed by a pathologist. Relapse of nephritis was the outcome of interest. Descriptive analysis of patients who did and those who did not have a relapse was performed by chi-square test, Fisher's exact test, and Wilcoxon 2-sample test. The cumulative rate of relapse was computed using the actuarial method. Univariate comparisons of time to relapse were computed by log-rank test. Proportional hazards modeling was used to assess the combined effect of patient characteristics that have been hypothesized to be prognostic factors. Nephritis relapsed in 11 patients. Previous hematologic disorder, arthritis or ar...Continue Reading

References

Aug 2, 1979·The New England Journal of Medicine·A S FauciS M Wolff
Oct 1, 1979·Annals of Internal Medicine·J L DeckerJ H Klippel
Oct 15, 1979·American Journal of Obstetrics and Gynecology·L D Devoe, R L Taylor
Jan 1, 1977·Godis̆en Zbornik Na Medicinskiot Fakultet Vo Skopje·M PolenakovićL Grcevska
May 1, 1978·Nihon rinsho. Japanese journal of clinical medicine·T Ofuji
Mar 15, 1992·Annals of Internal Medicine·G S HoffmanA S Fauci
Aug 1, 1991·Seminars in Arthritis and Rheumatism·M PistinerJ R Klinenberg
Jan 1, 1990·Indian Journal of Pathology & Microbiology·N JayaramS Sehgal
Apr 1, 1989·British Journal of Rheumatology·E N HarrisK De Ceulaer
Aug 1, 1989·The American Journal of Medicine·R S LaitmanN Bank
Apr 21, 1988·The New England Journal of Medicine·J Pedersen-BjergaardM M Hansen
Mar 6, 1986·The New England Journal of Medicine·H A AustinJ L Decker
Oct 1, 1987·Southern Medical Journal·V HarisdangkulL Rockhold
Sep 1, 1983·The American Journal of Medicine·H A AustinJ E Balow
Jun 1, 1982·Arthritis and Rheumatism·S RosnerE V Barnett
Jul 1, 1982·Arthritis and Rheumatism·R T McCluskey
Nov 1, 1982·Arthritis and Rheumatism·E M TanR J Winchester
Aug 1, 1995·British Journal of Rheumatology·M R Gonzalez-CrespoV Rodriguez-Valverde
Mar 1, 1994·Arthritis and Rheumatism·J M EsdaileM Kashgarian
Feb 1, 1994·American Journal of Kidney Diseases : the Official Journal of the National Kidney Foundation·L A WardD A Feinfeld

❮ Previous
Next ❯

Citations

May 16, 2001·Current Rheumatology Reports·E M Ginzler
Jul 2, 2008·Immunologic Research·Stephen H Clarke
Jun 16, 2001·International Immunopharmacology·M MoscaG R Hughes
Dec 22, 2010·Nature Reviews. Nephrology·Vladimir Tesar, Zdenka Hruskova
Jul 18, 2012·Nature Reviews. Nephrology·Jon W Gregersen, David R W Jayne
Nov 14, 2012·Nature Reviews. Nephrology·Ben SprangersGerald B Appel
Sep 13, 2003·Immunology and Cell Biology·Caroline Tan SardjonoP Mark Hogarth
Mar 29, 2002·Kidney International·Marta MoscaStefano Bombardieri
Jun 30, 2005·Nephrology, Dialysis, Transplantation : Official Publication of the European Dialysis and Transplant Association - European Renal Association·Ana CarlavillaManuel Praga
Aug 19, 2003·Annals of the Rheumatic Diseases·C C MokK N Lai
Apr 13, 2005·Nephron. Clinical Practice·Jane CrossUNKNOWN Renal Association Clinical Trials Subcommittee
Jan 8, 2003·Drugs·Dudy G Kuiper-Geertsma, Ronald H W M Derksen
Nov 16, 2007·Clinical Journal of the American Society of Nephrology : CJASN·Yiann E ChenUNKNOWN Collaborative Study Group
Nov 26, 2013·Reumatología clinica·Dafhne Miranda-HernándezMiguel Angel Saavedra
Oct 17, 2006·Journal of Clinical Rheumatology : Practical Reports on Rheumatic & Musculoskeletal Diseases·Ximena VelásquezSergio Jacobelli
Apr 30, 2010·Digestive Diseases and Sciences·Albert J Czaja
Jan 5, 2002·Expert Opinion on Investigational Drugs·G G Illei, L Czirják
Mar 1, 2006·Expert Opinion on Investigational Drugs·Felix Braun, Matthias Behrend
Sep 4, 2010·Autoimmunity Reviews·Andrea DoriaLuca Iaccarino
Jan 1, 2006·Reumatología clinica·F G Arévalo-MartínezJ J Badía-Flores
Jul 1, 2008·Reumatología clinica·Lucía Silva FernándezEllen M Ginzler
Jan 1, 2007·Reumatología clinica·Juan Manuel MirandaUlises Angeles
Jan 16, 1999·Baillière's Clinical Rheumatology·J H Klippel
May 10, 2005·Nephrology·Kar Neng LaiChi Chiu Mok
Mar 19, 2014·Alimentary Pharmacology & Therapeutics·A J Czaja
Apr 18, 2000·Rheumatic Diseases Clinics of North America·R A Ortmann, J H Klippel
Jun 4, 2002·Best Practice & Research. Clinical Rheumatology·John M Esdaile
Feb 1, 2014·Autoimmunity Reviews·Andrea DoriaLeonardo Punzi
Sep 15, 2000·Rheumatology·H C Nossent, W Koldingsnes
Sep 26, 2015·Lupus·J M Mejía-ViletR Correa-Rotter
May 1, 2013·Lupus·P Vachvanichsanong, E McNeil
Jan 12, 1999·Lupus·D T Boumpas, J E Balow
Mar 1, 2005·Lupus·C C Mok
Mar 1, 2005·Lupus·P I SidiropoulosD T Boumpas

❮ Previous
Next ❯

Related Concepts

Trending Feeds

COVID-19

Coronaviruses encompass a large family of viruses that cause the common cold as well as more serious diseases, such as the ongoing outbreak of coronavirus disease 2019 (COVID-19; formally known as 2019-nCoV). Coronaviruses can spread from animals to humans; symptoms include fever, cough, shortness of breath, and breathing difficulties; in more severe cases, infection can lead to death. This feed covers recent research on COVID-19.

Blastomycosis

Blastomycosis fungal infections spread through inhaling Blastomyces dermatitidis spores. Discover the latest research on blastomycosis fungal infections here.

Nuclear Pore Complex in ALS/FTD

Alterations in nucleocytoplasmic transport, controlled by the nuclear pore complex, may be involved in the pathomechanism underlying multiple neurodegenerative diseases including Amyotrophic Lateral Sclerosis and Frontotemporal Dementia. Here is the latest research on the nuclear pore complex in ALS and FTD.

Applications of Molecular Barcoding

The concept of molecular barcoding is that each original DNA or RNA molecule is attached to a unique sequence barcode. Sequence reads having different barcodes represent different original molecules, while sequence reads having the same barcode are results of PCR duplication from one original molecule. Discover the latest research on molecular barcoding here.

Chronic Fatigue Syndrome

Chronic fatigue syndrome is a disease characterized by unexplained disabling fatigue; the pathology of which is incompletely understood. Discover the latest research on chronic fatigue syndrome here.

Evolution of Pluripotency

Pluripotency refers to the ability of a cell to develop into three primary germ cell layers of the embryo. This feed focuses on the mechanisms that underlie the evolution of pluripotency. Here is the latest research.

Position Effect Variegation

Position Effect Variagation occurs when a gene is inactivated due to its positioning near heterochromatic regions within a chromosome. Discover the latest research on Position Effect Variagation here.

STING Receptor Agonists

Stimulator of IFN genes (STING) are a group of transmembrane proteins that are involved in the induction of type I interferon that is important in the innate immune response. The stimulation of STING has been an active area of research in the treatment of cancer and infectious diseases. Here is the latest research on STING receptor agonists.

Microbicide

Microbicides are products that can be applied to vaginal or rectal mucosal surfaces with the goal of preventing, or at least significantly reducing, the transmission of sexually transmitted infections. Here is the latest research on microbicides.